Risk assessment in pulmonary arterial hypertension
Eur Respir J
.
2018 Mar 29;51(3):1702606.
doi: 10.1183/13993003.02606-2017.
Print 2018 Mar.
Authors
Marius M Hoeper
1
2
,
David Pittrow
3
,
Christian Opitz
4
,
J Simon R Gibbs
5
,
Stephan Rosenkranz
6
7
,
Ekkehard Grünig
2
8
,
Karen M Olsson
9
2
,
Doerte Huscher
10
Affiliations
1
Dept of Respiratory Medicine, Hannover Medical School, Hannover, Germany hoeper.marius@mh-hannover.de.
2
German Center of Lung Research (DZL), Germany.
3
Institute for Clinical Pharmacology, Medical Faculty, Technical University, Dresden, Germany.
4
Dept of Cardiology, DRK Kliniken Berlin Westend, Berlin, Germany.
5
Dept of Cardiology, National Heart and Lung Institute, Imperial College London, London, UK.
6
Clinic III for Internal Medicine (Cardiology) and Center for Molecular Medicine (CMMC), University of Cologne, Cologne, Germany.
7
The Cologne Cardiovascular Research Center (CCRC), University of Cologne, Cologne, Germany.
8
Thoraxclinic at the University Hospital Heidelberg, Heidelberg, Germany.
9
Dept of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
10
Epidemiology Unit, German Rheumatism Research Centre, A. Leibniz Institute, Berlin, Germany.
PMID:
29599117
DOI:
10.1183/13993003.02606-2017
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Familial Primary Pulmonary Hypertension*
Humans
Hypertension, Pulmonary*
Prognosis
Risk Assessment